Lexicon Pharmaceuticals Inc (LXRX)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Lexicon Pharmaceuticals Inc chart...

About the Company

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Exchange

NASDAQ

Website

lexpharma.com

$0M

Total Revenue

304

Employees

$536M

Market Capitalization

-3.06

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LXRX News

Crude Oil Edges Higher; Lexicon Pharmaceuticals Shares Jump

17d ago, source:

U.S. stocks traded lower midway through trading, with the Dow Jones index dipping over 50 points on Monday. The Dow traded ...

FILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS

8h ago, source:

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael ...

William Blair starts Solid Biosciences at outperform

on MSN ago, source:

William Blair has initiated coverage of Solid Biosciences (SLDB) with an outperform rating, citing market opportunities in ...

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

on MSN ago, source:

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary ...

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday

1d ago, source:

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday U.S. stocks were ...

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why

on MSN ago, source:

Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead ...

LSPedia Awarded National DSCSA Compliance Agreement with Premier, Inc.

17d ago, source:

LSPedia today announced it has been awarded a national group purchasing agreement with Premier, Inc., offering Premier's U.S. Hospitals complete DSCSA compliance, recall management, and supply chain ...

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

16d ago, source: Hosted on MSN

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA ...

Stocks Fluctuate Before Feb ISM Manufacturing Report

21y ago, source: The Globe and Mail

The S&P 500 Index ($SPX) (SPY) this morning is up +0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.07%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up ...

Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics

2d ago, source: TMCnet

Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024; Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...